Anoop TM, Joseph P R, Soman S, Chacko S, Mathew M. Significance of serum carcinoembryonic antigen in metastatic breast cancer patients: A prospective study. World J Clin Oncol 2022; 13(6): 529-539 [PMID: 35949431 DOI: 10.5306/wjco.v13.i6.529]
Corresponding Author of This Article
Thattungal Manoharan Anoop, MD, DM, DNB, Associate Professor, Department of Medical Oncology, Regional Cancer Center, Medical College Campus, Trivandrum 695011, Kerala, India. dranooptm@yahoo.co.in
Research Domain of This Article
Oncology
Article-Type of This Article
Prospective Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Oncol. Jun 24, 2022; 13(6): 529-539 Published online Jun 24, 2022. doi: 10.5306/wjco.v13.i6.529
Table 1 Association of baseline serum carcinoembryonic antigen with other variables in study population
CEA level
Less than or equal to 3.8
More than 3.8
P value
Pre-menopausal
3
9
0.79
Post-menopausal
11
27
Grade 2
3
9
0.79
Grade 3
11
27
Luminal
6
30
0.016
Her2 Neu
1
2
TNBC
7
4
Luminal
6
30
0.012
Non luminal
8
6
Bone metastases
6
19
0.682
No bone metastases
7
17
Lung metastases
11
25
0.487
No lung metastases
2
11
Liver metastases
3
15
0.392
No liver metastases
10
21
Less than 5 metastases
1
2
0.78
More than 5
12
34
PR/SD/CR
9
23
0.79
Progression
5
13
Table 2 Serum carcinoembryonic antigen and response to treatment in responders and non-responders
Serum CEA
Responders
Non-responders
P value
Median pre-treatment serum CEA
8.87 (2-49.6)
5.4 (1.7-36.01)
0.527
Median post-treatment serum CEA
2.07 (1-8.7)
11 (4.65-22.5)
0.002
P value
0.001
0.06
Table 3 Serum carcinoembryonic antigen and response to treatment in responders and non-responders according to breast cancer type
Classification
Responders
Non-responders
Median pre-CEA
Median post-CEA
P value
Median pre-CEA
Median post-CEA
P value
Hormonal classification
Luminal
14.7 (5.4-50.6)
3 (1-10)
0.001
22.39 (3.9-84.4)
21.00 (10.6-164.15)
0.26
Non-luminal
1.85 (1-3.65)
1.25 (0.5-3)
0.046
4.15 (0.85-10.17)
5.65 (2.65-12.05)
0.161
Genomic classification
Luminal
14.7 (5.4-50.6)
3 (1-10)
0.001
22.39 (3.9-84.47)
20.67 (10.6-164.17)
0.260
HER2
4 (1.2-4)
3.25 (0.5-3.25)
0.18
11.7
13
_
TNBC
1.85 (0.74-2.4)
1.25 (0.67-1.88)
0.144
4 (0.5-5.6)
5.3 (2.2-9.2)
0.237
Table 4 Serum carcinoembryonic antigen and response to treatment in bone, liver, and lung metastases
Serum CEA (ng/mL)
Bone metastases
No bone metastases
P value
Median pre-treatment serum CEA
11.7 (2.9-48.4)
6.8 (2-32.3)
0.788
Median post-treatment serum CEA
9 (2-20)
2 (1-9)
0.063
Liver metastases
No liver metastases
Median pre-treatment serum CEA
11.7 (4.4-62.7)
6.8 (1.9-22.7)
0.244
Median post-treatment serum CEA
8 (1.2-19.75)
3 (1.25-11.5)
0.352
Lung metastases
No lung metastases
Median pre-treatment serum CEA
7.8 (1.9-31.3)
9.78 (5.15-66.64)
0.353
Median post-treatment serum CEA
3.5 (1-13.75)
5 (1.5-10)
0.93
Citation: Anoop TM, Joseph P R, Soman S, Chacko S, Mathew M. Significance of serum carcinoembryonic antigen in metastatic breast cancer patients: A prospective study. World J Clin Oncol 2022; 13(6): 529-539